Posted on

As of 08 July 2026, the HTA Council has completed the evidence appraisal on the assessment of ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for the treatment of hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) in adult hospitalized patients ≥18 years.

As a preliminary recommendation, the HTA Council recommends the government financing of the following:

  • ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] for HAP/VAP caused by carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA); and
  • ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for HAP/VAP caused by CRPA.

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 08 to 22 July 2026, for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format and those submitted beyond the deadline shall not be entertained.

Preliminary HTA Council Recommendation on Ceftazidime_Avibactam and Ceftolozane_Tazobactam for HAP and VAP (08 July 2026)Download
[Evidence to Recommendation] Ceftazidime_Avibactam and Ceftolozane_Tazobactam for HAP and VAPDownload